On July 31, 2026, a status update was recorded for the phase 3 trial NCT02115282, which is tracked under goserelin. The study is titled "Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic." According to the update, the trial's current status is active but not recruiting new participants. The trial is registered as a phase 3 study focused on patients with recurrent, hormone receptor-positive breast cancer that is locally advanced or metastatic. No results or outcome data were included in this update. The listing confirms only the trial's design elements, phase designation, and current recruitment status as of the stated date. This update does not report efficacy findings, safety conclusions, or comparative outcomes between treatment arms. Readers seeking further detail on the trial's design or status can consult the official registration at the provided source link. For background on goserelin as a compound, readers can refer to the compound overview.
Goserelin: Phase 3 Trial Update on Exemestane Plus Entinostat Reported
See the full goserelin overview
Source: https://clinicaltrials.gov/study/NCT02115282